Radnor Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.57M | Sell |
79,233
-465
| -0.6% | -$26.7K | 0.64% | 30 |
|
|
2026
Q1 | $4.83M | Buy |
79,698
+1,340
| +2% | +$78.1K | 0.72% | 28 |
|
|
2025
Q4 | $4.23M | Buy |
78,358
+1,785
| +2% | +$85.9K | 0.63% | 32 |
|
|
2025
Q3 | $3.45M | Sell |
76,573
-5,368
| -7% | -$251K | 0.53% | 46 |
|
|
2025
Q2 | $3.79M | Buy |
81,941
+1,150
| +1% | +$56.5K | 0.61% | 38 |
|
|
2025
Q1 | $4.93M | Sell |
80,791
-75
| -0.1% | -$4.37K | 0.83% | 23 |
|
|
2024
Q4 | $4.57M | Sell |
80,866
-8,600
| -10% | -$481K | 0.76% | 22 |
|
|
2024
Q3 | $4.63M | Buy |
+89,466
| New | +$4.2M | 0.69% | 29 |
|
|
2024
Q2 | – | Sell |
-66,823
| Closed | -$3.62M | – | 169 |
|
|
2024
Q1 | $3.62M | Sell |
66,823
-169
| -0.3% | -$8.61K | 0.62% | 35 |
|
|
2023
Q4 | $3.44M | Sell |
66,992
-2,914
| -4% | -$153K | 0.64% | 30 |
|
|
2023
Q3 | $4.06M | Buy |
+69,906
| New | +$4.28M | 0.81% | 22 |
|
|
2023
Q2 | – | Sell |
-54,866
| Closed | -$3.8M | – | 145 |
|
|
2023
Q1 | $3.8M | Buy |
54,866
+2,780
| +5% | +$196K | 1% | 17 |
|
|
2022
Q4 | $4.03M | Sell |
52,086
-35
| -0.1% | -$2.64K | 0.99% | 15 |
|
|
2022
Q3 | $3.71M | Sell |
52,121
-40
| -0.1% | -$2.9K | 1.07% | 14 |
|
|
2022
Q2 | $4.02M | Buy |
52,161
+2,275
| +5% | +$173K | 1.1% | 15 |
|
|
2022
Q1 | $3.64M | Sell |
49,886
-30
| -0.1% | -$2.01K | 0.91% | 19 |
|
|
2021
Q4 | $3.11M | Buy |
+49,916
| New | +$2.93M | 0.77% | 26 |
|
|
2021
Q3 | – | Sell |
-47,716
| Closed | -$3.19M | – | 114 |
|
|
2021
Q2 | $3.19M | Buy |
47,716
+155
| +0.3% | +$10.1K | 1.08% | 18 |
|
|
2021
Q1 | $3M | Buy |
47,561
+2,825
| +6% | +$176K | 0.97% | 21 |
|
|
2020
Q4 | $2.77M | Buy |
44,736
+580
| +1% | +$35.7K | 0.78% | 25 |
|
|
2020
Q3 | $2.66M | Sell |
44,156
-1,000
| -2% | -$60.2K | 0.89% | 25 |
|
|
2020
Q2 | $2.68M | Buy |
45,156
+644
| +1% | +$38.5K | 0.97% | 22 |
|
|
2020
Q1 | $2.48M | Sell |
44,512
-382
| -0.9% | -$23.3K | 1.02% | 22 |
|
|
2019
Q4 | $2.88M | Hold |
44,894
| – | – | 0.89% | 26 |
|
|
2019
Q3 | $2.28M | Buy |
44,894
+700
| +2% | +$32.9K | 0.75% | 29 |
|
|
2019
Q2 | $2M | Buy |
44,194
+3,475
| +9% | +$162K | 0.66% | 34 |
|
|
2019
Q1 | $1.94M | Buy |
40,719
+1,925
| +5% | +$95.9K | 0.64% | 34 |
|
|
2018
Q4 | $2.02M | Buy |
38,794
+1,000
| +3% | +$53.7K | 0.73% | 28 |
|
|
2018
Q3 | $2.35M | Buy |
37,794
+3,200
| +9% | +$190K | 0.75% | 28 |
|
|
2018
Q2 | $1.91M | Sell |
34,594
-1,700
| -5% | -$91.8K | 0.71% | 34 |
|
|
2018
Q1 | $2.3M | Sell |
36,294
-300
| -0.8% | -$19.3K | 0.78% | 28 |
|
|
2017
Q4 | $2.24M | Hold |
36,594
| – | – | 0.72% | 33 |
|
|
2017
Q3 | $2.04M | Hold |
36,594
| – | – | 0.69% | 34 |
|
|
2017
Q2 | $2.04M | Hold |
36,594
| – | – | 0.69% | 34 |
|
|
2017
Q1 | $1.99M | Buy |
36,594
+1,150
| +3% | +$63.1K | 0.67% | 34 |
|
|
2016
Q4 | $2.07M | Buy |
+35,444
| New | +$1.94M | 0.71% | 29 |
|
Other funds holding BMY
AIM
FWIA
DLA
ETC
Radnor Capital Management's BMY Position: Q2 2026 in Review
Radnor Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.58% in Q2 2026, selling an estimated $26.7K and leaving 79,233 shares worth $4.57M. The position accounts for 0.64% of the portfolio, ranked #30.
Radnor Capital Management first reported a position in BMY in Q4 2016 and has held it in 36 quarters since. The position peaked at $4.93M in Q1 2025. 848 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Radnor Capital Management held 79,233 shares of Bristol-Myers Squibb worth $4.57M as of Q2 2026.
- Radnor Capital Management sold 465 Bristol-Myers Squibb shares in Q2 2026, an estimated $26.7K.
- Bristol-Myers Squibb made up 0.64% of Radnor Capital Management's portfolio in Q2 2026, its #30 holding.
- Radnor Capital Management first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 36 quarters since.
- Radnor Capital Management's Bristol-Myers Squibb position peaked at $4.93M in Q1 2025.
- 848 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Radnor Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.